who we are?
Innovative Drug Discovery for Metabolic Disease & Cancer
MitoCareX Bio is an innovative drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company focuses on a previously underexploited class of drug targets: mitochondrial SLC25 transport proteins, which play a central role in cellular energy metabolism yet have historically been considered difficult or impossible to drug due to their membrane localization and structural complexity.
Our Platform
MITOLINE™: The Discovery Engine at Our Core
At the core of MitoCareX Bio's discovery engine is MITOLINE™, a proprietary computational platform designed to enable reliable homology modeling of mitochondrial membrane proteins, particularly transport proteins. By enabling accurate 3D structural modeling and large-scale virtual screening, MITOLINE™ opens access to a novel and largely untapped target space, allowing MitoCareX to identify small-molecule modulators capable of directly disrupting disease-associated metabolic pathways while potentially minimizing systemic toxicity.
Our Approach
Integrated Discovery: In Silico Meets Experimental Rigor
MitoCareX Bio integrates advanced in silico discovery with rigorous experimental validation, creating a capital-efficient pipeline that rapidly translates computational insights into biologically validated drug candidates. This approach is designed not only to accelerate the discovery of high-quality therapeutic assets targeting inflammatory metabolic diseases and cancer metabolism, but also to generate significant long-term value through partnerships, licensing opportunities, and scalable platform applications.
🧬
In Silico Discovery
Advanced computational methods via MITOLINE™ rapidly identify high-value candidates.
🔬
Experimental Validation
Rigorous wet-lab validation confirms biological activity and on-target engagement.
🚀
Long-Term Value
Partnerships, licensing, and scalable platform applications drive commercial growth.
Vision & Ecosystem
A Powerful Convergence of Technology, Science & Commercial Potential
With a strong translational focus and a clear path toward clinical relevance, MitoCareX Bio aims to unlock mitochondrial biology to deliver transformative metabolic therapies. As part of the Nexentis Technologies Inc. ecosystem, MitoCareX Bio represents a powerful convergence of proprietary technology, deep scientific expertise, and commercial potential, positioning it at the forefront of the next generation of mitochondrial drug discovery.
Visit